Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

A recent study highlights the critical impact of comorbidities on survival rates in melanoma patients, emphasizing the need ...

TARA-002 achieved a 72% complete response rate in BCG-naive NMIBC patients, with durable responses at 6 and 12 months. The ...

QBS72S, a LAT1-targeted agent, shows potential in treating leptomeningeal disease, improving survival rates in metastatic ...

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative ...

Additionally, beyond adapting existing drug combinations, cutting-edge therapies such as bispecific antibodies and CAR T-cell ...

JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

The FDA has granted traditional approval to pirtobrutinib (Jaypirca) for the treatment of adult patients with relapsed or ...

As Dr Voorhees mentioned in part 2, the definition of high-risk SMM has evolved over time and is subject to change in the ...

IGV-001, an investigational autologous cell immunotherapeutic combination product, may offer clinically meaningful overall ...

Dr. Peter Voorhees discusses groundbreaking AQUILA study results, highlighting daratumumab's significant impact on high-risk ...